Skip to main content
Year archive

argenx SE — 2018 filings

All 65 regulatory filings released by argenx SE (1AE) in 2018, sourced directly from the official regulator.

65 Filings
2018 Period
2018 filings (65)
Filing Released Lang
6-K
Foreign Filer Report
2018-12-03 English
6-K
Foreign Filer Report
2018-12-03 English
argenx Provides Detailed Data from Phase 2 Clinical Trial of Efgartigimod in Immune Thrombocytopenia and Phase 1/2 Clinical Trial of Cusatuzumab in Acute Myeloid Leukemia
Earnings Release Q4 2018
2018-12-03 English
argenx enters exclusive global collaboration and license agreement with Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)
Regulatory Filings
2018-12-03 English
argenx to Present at Upcoming Investor Conferences
Report Publication Announcement
2018-11-07 English
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts published in connection with 60th American Society of Hematology Annual Meeting and Exposition
Earnings Release Q3 2018
2018-11-01 English
6-K
Foreign Filer Report
2018-11-01 English
6-K
Foreign Filer Report
2018-10-25 English
argenx reports third quarter 2018 financial results and provides business update
Interim / Quarterly Report 9M 2018
2018-10-25 English
6-K
Foreign Filer Report
2018-10-09 English
argenx awarded €2.6 million VLAIO grant to explore new applications of ABDEG technology
Capital/Financing Update
2018-10-09 English
argenx announces closing of U.S. public offering for gross proceeds of approximately $300.6 million
Share Issue/Capital Change
2018-09-24 English
6-K
Foreign Filer Report
2018-09-20 English
424B5
Prospectus
2018-09-20 English
Interim / Quarterly Report 2018
Interim / Quarterly Report H1 2018
2018-09-19 English
argenx raises approximately $300.6 million in gross proceeds in a U.S. public offering
Share Issue/Capital Change
2018-09-19 English
argenx announces launch of proposed public offering in the United States
Share Issue/Capital Change
2018-09-18 English
424B5
Prospectus
2018-09-17 English
6-K
Foreign Filer Report
2018-09-17 English
argenx reports positive topline results from Phase 2 proof-of-concept trial of efgartigimod in primary immune thrombocytopenia
Earnings Release Q3 2018
2018-09-17 English
Major Shareholding Notification 2018
Major Shareholding Notification
2018-09-10 English
6-K
Foreign Filer Report
2018-09-06 English
argenx doses first patient in global Phase 3 registration trial of efgartigimod for the treatment of generalized myasthenia gravis
Regulatory Filings
2018-09-06 English
6-K
Foreign Filer Report
2018-08-29 English
argenx receives feedback from Japan's PMDA on Phase 3 clinical trial and regulatory pathway for efgartigimod in generalized myasthenia gravis
Earnings Release Q3 2018
2018-08-29 English
6-K
Foreign Filer Report
2018-08-22 English
argenx announces that AbbVie has exercised its exclusive option to license ARGX-115, a novel immuno-oncology antibody
Capital/Financing Update
2018-08-22 English
argenx to Present at 2018 Wedbush PacGrow Healthcare Conference
Regulatory Filings
2018-08-10 English
6-K
Foreign Filer Report
2018-08-02 English
argenx reports second quarter business update and half-year 2018 financial results
Interim / Quarterly Report H1 2018
2018-08-02 English
argenx to host conference call & webcast to report second quarter business update and half year 2018 financial results on August 2, 2018
Report Publication Announcement
2018-07-26 English
argenx announces publication of full data from Phase 1 healthy volunteer study of efgartigimod in Journal of Clinical Investigation
Regulatory Filings
2018-07-25 English
6-K
Foreign Filer Report
2018-07-24 English
6-K
Foreign Filer Report
2018-07-17 English
argenx receives milestone payment from strategic collaboration with Shire
Regulatory Filings
2018-07-17 English
6-K
Foreign Filer Report
2018-06-28 English
argenx receives second preclinical milestone payment under its development agreement with AbbVie
Earnings Release Q2 2018
2018-06-28 English
6-K
Foreign Filer Report
2018-06-20 English
argenx reports interim data from first cohort of Phase 2 proof-of-concept clinical trial of efgartigimod for the treatment of pemphigus vulgaris
Earnings Release Q2 2018
2018-06-20 English
6-K
Foreign Filer Report
2018-06-14 English
argenx announces data from Phase 1 study of efgartigimod (ARGX-113) subcutaneous formulation demonstrating comparable characteristics to intravenous formulation
Regulatory Filings
2018-06-14 English
argenx to host KOL breakfast symposium on immune thrombocytopenia on June 19, 2018
Regulatory Filings
2018-06-12 English
6-K
Foreign Filer Report
2018-06-07 English
argenx selected for BEL 20 Index
Regulatory Filings
2018-06-06 Dutch
argenx receives feedback from FDA in end-of-phase 2 meeting for efgartigimod in myasthenia gravis
Regulatory Filings
2018-06-06 English
S-8
Registration Form
2018-06-01 English
F-3ASR
Regulatory Filings
2018-06-01 English
6-K
Foreign Filer Report
2018-05-09 English
argenx reports first quarter 2018 financial results and provides business update
Earnings Release Q1 2018
2018-05-09 English
argenx announces results of Annual General Meeting of Shareholders
AGM Information
2018-05-08 English
6-K
Foreign Filer Report
2018-04-24 English
argenx to present complete data from the Phase 2 proof-of-concept trial of efgartigimod (ARGX-113) in
Earnings Release Q2 2018
2018-04-24 English
6-K
Foreign Filer Report
2018-04-12 English
argenx to receive third preclinical milestone payment from collaboration with LEO Pharma - Milestone associated with CTA approval for ARGX-112
Regulatory Filings
2018-04-12 English
6-K
Foreign Filer Report
2018-04-09 English
argenx appoints Keith Woods as Chief Operating Officer
Board/Management Information
2018-04-09 English
Annual Report 2017
Annual Report FY 2017
2018-03-27 English
20-F
Annual Report FY 2017
2018-03-26 English
6-K
Foreign Filer Report
2018-03-26 English
argenx announces orphan drug designation for ARGX-113 for the treatment of myasthenia gravis in Europe
Regulatory Filings
2018-03-26 English
6-K
Foreign Filer Report
2018-03-22 English
6-K
Foreign Filer Report
2018-03-16 English
argenx awarded €2.5 million VLAIO grant to identify novel therapeutic antibodies
Regulatory Filings
2018-03-16 English
6-K
Foreign Filer Report
2018-03-01 English
argenx to host conference call & webcast to report fourth quarter business update and full year 2017 financial results on March 1, 2018
Earnings Release Q4 2017
2018-02-22 English